Diabetes Therapeutics Market Report 2025

The diabetes therapeutics market size has grown rapidly in recent years. It will grow from $153.67 billion in 2024 to $170.06 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth during the historic period can be attributed to the early rise in diabetes prevalence, broad adoption of oral hypoglycemic agents, initial use of injectable insulin therapies, increased awareness and education on self-management, and the introduction of biosimilar insulins into the market.

The diabetes therapeutics market size is expected to see rapid growth in the next few years. It will grow to $252.95 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth during the forecast period can be attributed to rising digital literacy, growing adoption of non-insulin injectable drugs, the expansion of digital health platforms, increasing demand for personalized and combination therapies, and enhancements in healthcare infrastructure and access to diabetes care. Key trends anticipated in the forecast period include automated insulin delivery (AID) systems, the use of artificial intelligence (AI) in diabetes management, improved device interoperability, the rise of digital health applications, and the advancement of remote patient monitoring (RPM).

The growing prevalence of obesity is expected to drive the expansion of the diabetes therapeutics market in the coming years. Obesity, characterized by excessive fat accumulation that poses a health risk, is a major contributing factor to type 2 diabetes. This rise in obesity is largely attributed to the increasing consumption of high-calorie diets, including processed and fast foods high in sugar and fat, coupled with declining physical activity, which leads to excessive weight gain. Diabetes therapeutics assist in managing obesity by improving blood sugar control and promoting weight loss through medications such as GLP-1 receptor agonists, which help reduce appetite and slow digestion, thereby enhancing metabolic health in obese individuals. For example, in May 2024, a report by the Office for Health Improvement and Disparities, a UK-based government department, revealed that between 2022 and 2023, approximately 64% of adults aged 18 and older were classified as overweight or living with obesity, up from 63.8% the previous year. As a result, the increasing prevalence of obesity is contributing to the growth of the diabetes therapeutics market.

Key companies in the diabetes therapeutics space are developing innovative approaches, such as cognitive behavioral therapy (CBT), to support personalized diabetes care and improve glycemic control in patients with type 2 diabetes. CBT is a structured, evidence-based psychological treatment that helps individuals recognize and change unhelpful thought patterns and behaviors. For instance, in October 2023, Better Therapeutics Inc., a U.S.-based digital therapeutics company, launched AspyreRx, a digital therapeutic app for diabetes. Approved by the FDA for treating type 2 diabetes, AspyreRx delivers tailored CBT to patients aged 18 and older, promoting behavior changes that enhance diabetes management. Previously known as BT-001, the app showed statistically and clinically significant, sustained reductions in A1c levels compared to standard care, along with improvements in blood pressure, weight, mood, and quality of life in a randomized controlled trial.

In June 2023, Eli Lilly and Company, a U.S.-based pharmaceutical firm, acquired Sigilon Therapeutics Inc. for $0.034 billion. The acquisition aims to strengthen Eli Lilly’s diabetes care portfolio by advancing innovative cell therapies for type 1 diabetes. Specifically, it focuses on the continued development of Sigilon’s SIG-002 program, which seeks to restore natural insulin production using encapsulated islet cell replacement. This approach has the potential to provide a functional cure for type 1 diabetes and significantly reduce the daily disease management burden for patients. Sigilon Therapeutics Inc. is a U.S.-based biotechnology company specializing in diabetes therapeutics.

Major players in the diabetes therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Tandem Diabetes Care Inc., Lexicon Pharmaceuticals Inc., Better Therapeutics Inc., Adocia S.A., and Oramed Pharmaceuticals Inc.

North America was the largest region in the diabetes therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetes therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the diabetes therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetes therapeutics market consists of revenues earned by entities by providing services such as blood sugar monitoring, medication management, insulin therapy support, and lifestyle counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetes therapeutics market also includes sales of insulin, oral hypoglycemic agents, GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The diabetes therapeutics market research report is one of a series of new reports that provides diabetes therapeutics market statistics, including diabetes therapeutics industry global market size, regional shares, competitors with a diabetes therapeutics market share, diabetes therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes therapeutics industry. This diabetes therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetes therapeutics encompasses the range of medical treatments and interventions aimed at managing and controlling diabetes, a condition marked by elevated blood sugar levels resulting from issues with insulin production or utilization. These treatments include medications such as insulin (crucial for type 1 diabetes and sometimes used in type 2), oral drugs like metformin, and newer options such as GLP-1 receptor agonists and SGLT2 inhibitors, which lower blood glucose through different mechanisms.

The primary categories of drugs in diabetes therapeutics include oral anti-diabetic drugs, insulin, non-insulin injectable drugs, and combination drugs. Oral anti-diabetic drugs are taken by mouth to reduce blood sugar levels in individuals with diabetes. The condition is primarily classified into type 1 and type 2 diabetes. Routes of administration vary and include oral, subcutaneous, and intravenous methods, with distribution occurring through channels such as online pharmacies, hospital pharmacies, and retail pharmacies, addressing applications in both prevention and treatment or care.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.